Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation

Summary3rd-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), including osimertinib, have reasonable efficacy in non –small-cell lung cancers (NSCLC) withEGFR mutations. However, the efficacy of osimertinib in NSCLC patients with fluids, such as pleural, pericardial and abdominal effusions, is unclear. We evaluated the efficacy of osimertinib in this specific setting. NSCLC patients harboringEGFR T790  M mutations who experienced progressive disease after first EGFR-TKI treatment and started osimertinib treatment between April 2016 and August 2018 were retrospectively screened. In particular, we assessed the efficacy of osimertinib for NSCLC withEGFR T790  M mutations in patients who were diagnosed withEGFR T790  M mutation by malignant effusion. Among 90 patients withEGFR T790  M mutation who started osimertinib treatment after EGFR-TKI failure, 21 were diagnosed from malignant effusions excluding cerebrospinal fluid (F group) and 69 using other methods including tissue biopsies (NF group). Patient characteristics were well-balanced between the two groups. Overall respon se was 50%, and significantly worse in the F group (29%) than the NF group (57%;P = 0.025). Median progression-free survival with osimertinib treatment in the F group (7.1 months, 95% confidence interval [CI]: 2.3–14.0) was significantly shorter than that in the NF group (11.9 months, 95% CI: 9.5–16.0;P =&thinsp...
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research

Related Links:

CONCLUSIONS We found that PVT1 promotes angiogenesis through targeting the miR-29c/VEGF signaling pathway in NSCLC. PMID: 31326971 [PubMed - in process]
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
Conditions:   Lung Cancer;   Non Small Cell Lung Cancer Interventions:   Drug: LMB-100;   Drug: pembrolizumab;   Diagnostic Test: Mesothelin Expression Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Source: OncoTargets and Therapy - Category: Cancer & Oncology Tags: OncoTargets and Therapy Source Type: research
The objective of this study was to develop a population-pharmacokinetic model of durvalumab in patients with various hematologic malignancies and to investigate the effects of demographic and disease factors on the pharmacokinetics in this population.MethodsA total of 1812 concentrations from 267 patients with myelodysplastic syndromes, acute myeloid leukemia, multiple myeloma, non-Hodgkin lymphoma, or Hodgkin lymphoma were included in the analysis.ResultsThe pharmacokinetics of durvalumab was adequately described by a two-compartment model with first-order elimination. A decrease in durvalumab clearance over time was main...
Source: Clinical Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research
Little understanding exists of referral patterns for patients with brain metastasis from non-small cell lung cancer (NSCLC) towards treatment with Gamma Knife radiosurgery (GKRS). Therefore, we explored current clinical daily practice and prognosis.
Source: Clinical Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
ConclusionPatients withKRAS-mutant lung adenocarcinoma have a poorer outcome on pemetrexed-based first-line chemotherapy. WhetherKRAS-mutant NSCLCs should be excluded from pemetrexed-containing regimens should be assessed prospectively.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
tier Gonçalves Recently, the development of immunotherapy through the immune checkpoint blockade led to long-lasting responses in several types of cancers that are refractory to conventional treatments, such as melanoma or non-small cell lung cancer. Immunotherapy has also demonstrated significant improvements in various other types of cancers. However, breast cancer remains one of the tumors that have not experienced the explosion of immunotherapy yet. Indeed, breast cancer was traditionally considered as being weakly immunogenic with a lower mutational load compared to other tumor types. In the last few yea...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Source: Biologics: Targets and Therapy - Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research
Publication date: August 2019Source: The Annals of Thoracic Surgery, Volume 108, Issue 2Author(s): David B. Nelson, Reza J. Mehran, Kyle G. Mitchell, Ravi Rajaram, Arlene M. Correa, Roland L. Bassett, Mara B. Antonoff, Wayne L. Hofstetter, Jack A. Roth, Boris Sepesi, Stephen G. Swisher, Garrett L. Walsh, Ara A. Vaporciyan, David C. RiceBackgroundIt is unclear whether the enhanced dexterity and visualization of the surgical robot lessens morbidity and influences staging or survival. We compared outcomes of robotic-assisted lobectomy (RAL) with thoracoscopic video-assisted lobectomy (VAL) or open lobectomy (OL) of non-small ...
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Investigational New Drugs | Lung Cancer | Non-Small Cell Lung Cancer | Study